Microlytic Gets $3.5M VC Investment | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Microlytic, a Copenhagen, Denmark-based protein crystallization tools firm, announced today that it has raised $3.5 million in venture capital funding.

The firm, which also has operations in Boston, plans to use the funds to expand sales and production of products for the structural biology market. It makes the Crystal Former device for crystallizing proteins and MCSG Screens, a set of crystallization reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."